Screener / SEC EDGAR /CIK 0001192448 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Instruments

GLAUKOS Corp GKOS

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. 10-K, Item 1

Employees
1,094
Headquarters
Aliso Viejo, CA
CEO
Thomas William Burns
Next results
around Jan 12, 2027
Compare with peers Embed

GKOS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 32.3%, above 82% of 154 peers (their median 10.4%) REVENUE GROWTH 32.3% · above 82% Gross margin: 64.8%, above 52% of 107 peers (their median 63.4%) GROSS MARGIN 64.8% · above 52% Operating margin: -25.5%, above 16% of 138 peers (their median 10.2%) OPERATING MARGIN -25.5% · above 16% Net margin: -24.6%, above 16% of 153 peers (their median 6.8%) NET MARGIN -24.6% · above 16% FCF margin: 5.2%, above 35% of 144 peers (their median 10.1%) FCF MARGIN 5.2% · above 35%
GKOS Peer median Below the median

What changed

11 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 23, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +78.8% ($60.7M to $108.6M) vs revenue +32.3% ($383.5M to $507.4M), +46.5 pts apart
  • Cash from operations −$14.8M vs net income −$187.7M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +10.2% ($57.7M to $63.6M) vs revenue +32.3% ($383.5M to $507.4M), -22.1 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Classification, completeness, and measurement of customer discounts and revenue related incentive programs
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

11 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 11 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Additionally, U.S. government shutdowns, including the shutdown that occurred in the fourth quarter of 2025, have impacted and could in the future impact certain regulatory agencies relevant to us, such as the U.S. FDA. Significant changes to operations at or the funding of such regulatory agencies could cause decreases in staff or…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We have and may continue to enter into acquisitions, collaborations, in-licensing agreements, joint ventures and partnerships in order to retain our competitive position within the marketplace, develop new products or expand into new markets. Examples include our acquisitions of Mobius Therapeutics, LLC, DOSE Medical, and Avedro, as…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Our enterprise resource planning (ERP) system is integral to our ability to accurately and efficiently maintain our books and records, record transactions, and prepare our financial statements. Any disruptions or
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We have incorporated and continue to further incorporate artificial intelligence into our internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business. We have and are continuing to incorporate…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$282.9M$314.7M$383.5M$507.4M
Net income−$99.2M−$134.7M−$146.4M−$187.7M
Operating cash flow−$33.1M−$57.8M−$61.3M−$14.8M
Free cash flow−$63.3M−$78.0M−$67.6M−$22.5M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$507.4M ▲ 32.3% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

9 filings in the last 30 days · SEC EDGAR

All filings
4 more

About the company

GLAUKOS Corp, Aliso Viejo, CA · from the 10-K filed Feb 23, 2026

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.

Headquarters
Aliso Viejo, CA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 28, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 1,094 full-time employees" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GKOS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.